These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2375136)

  • 1. Comparative bioavailability characteristics of commercial quinidine polygalacturonate and sulfate tablets.
    Dahl JR; Ueda CT; Meyers DG; Wulf BG
    DICP; 1990; 24(7-8):685-8. PubMed ID: 2375136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative bioavaiability of four commercial quinidine sulfate tablets.
    Strum JD; Colaizzi JL; Jaffe JM; Martineau PC; Poust RI
    J Pharm Sci; 1977 Apr; 66(4):539-42. PubMed ID: 576879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations.
    Frigo GM; Perucca E; Teggia-Droghi M; Gatti G; Mussini A; Salerno J
    Br J Clin Pharmacol; 1977 Aug; 4(4):449-54. PubMed ID: 901736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal absorption of quinidine from some solutions and commercial tablets.
    Guentert TW; Upton RA; Holford NH; Bostrom A; Riegelman S
    J Pharmacokinet Biopharm; 1980 Jun; 8(3):243-55. PubMed ID: 7420269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum quinidine levels after chronic administration of four different quinidine formulations.
    Soeterboek AM; Van Thiel M; Eng C
    J Int Med Res; 1976; 4(6):393-401. PubMed ID: 1027633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition kinetics of two oral forms of quinidine.
    Mahon WA; Mayersohn M; Inaba T
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):566-75. PubMed ID: 1277713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of two manufacturers' sustained-release quinidine gluconate tablets at steady state.
    Zinny MA; Taggart WV
    Clin Ther; 1984; 7(1):22-7. PubMed ID: 6518461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
    Bramer SL; Suri A
    Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate.
    Taggart WV; Holyoak W
    Clin Ther; 1983; 5(4):357-64. PubMed ID: 6871920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of caffeine on the oral absorption and disposition of quinidine.
    Zeller FP; Ueda CT; Wulf BG; Meyers DG
    Clin Pharm; 1984; 3(1):72-5. PubMed ID: 6697677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine.
    Bleske BE; Carver PL; Annesley TM; Bleske JR; Morady F
    J Clin Pharmacol; 1990 Oct; 30(10):911-5. PubMed ID: 2229451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasogastric administration of garenoxacin as crushed tablets with and without concomitant enteral feeding in healthy subjects.
    Krishna G; Noveck R; Vargas R; Grasela D; Wang Z
    Drugs R D; 2007; 8(1):43-50. PubMed ID: 17249848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of high pressure liquid chromatography and fluorescence polarization immunoassay to assess quinidine pharmacokinetics.
    Bottorff MB; Lalonde RL; Straughn AB
    Biopharm Drug Dispos; 1987; 8(3):213-21. PubMed ID: 3297181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of a commercial sustained-release quinidine tablet compared to oral quinidine solution.
    Sawyer WT; Pulliam CC; Mattocks A; Foster J; Hadzija BW; Rosenthal HM
    Biopharm Drug Dispos; 1982; 3(4):301-10. PubMed ID: 7159686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of food and an antacid on quinidine bioavailability.
    Ace LN; Jaffe JM; Kunka RL
    Biopharm Drug Dispos; 1983; 4(2):183-90. PubMed ID: 6882885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dietary fat content on the bioavailability of a sustained release quinidine gluconate tablet.
    Martinez MN; Pelsor FR; Shah VP; Skelly JP; Honigberg IL; Hemingway SM; Gallo JM; Kotzan JA; Zaman R; Brown WJ
    Biopharm Drug Dispos; 1990; 11(1):17-29. PubMed ID: 2322634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative bioavailability of ofloxacin tablets in comparison to oral solution.
    Malerczyk V; Verho M; Korn A; Rangoonwala R
    Curr Med Res Opin; 1987; 10(8):514-20. PubMed ID: 3479296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of three commercial sustained-release tablets of quinidine in maintenance therapy.
    Huynh-Ngoc T; Chabot M; Sirois G
    J Pharm Sci; 1978 Oct; 67(10):1456-9. PubMed ID: 702302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.